Close Menu

NEW YORK – Genentech said on Thursday that its Phase III IMpassion131 trial, investigating atezolizumab (Tecentriq) in combination with paclitaxel as a first-line option for metastatic, PD-L1-positive triple-negative breast cancer failed to meet its primary endpoint.

The drug giant didn't report detailed findings but issued a statement that the 650-patient randomized trial failed to demonstrate that the atezolizumab-paclitaxel combination statistically significantly improved progression-free survival compared to just paclitaxel in PD-L1-positive, metastatic TNBC patients. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.